NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
NovelStem International Corp., a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based affiliate, NewStem Ltd., today announced it has completed a $1 million follow-on investment in NewStem, increasing its ownership in NewStem to 27.3% from 20%.